Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands

Current Topics in Medicinal Chemistry

Volumn 6, Issue 12, 2006, Pages 1243-1253

  Carlberg, Carsten ^a   Molnár, Ferdinand ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Coactivator proteins; Corepressor proteins; Nuclear receptor signaling; Vitamin D; Vitamin D analogues; Vitamin D receptor

Indexed keywords

1,3,24 TRIHYDROXY 26,27 CYCLO 9,10 SECOCHOLESTA 5,7,10(19),22 TETRAENE 25 CARBOXYLIC ACID BUTYL ESTER; 1ALPHA HYDROXY 2 METHYLENE 19 NOR 20 BISHOMOPREGNACALCIFEROL; 2 METHYLENE 19 NOR 20 CALCITRIOL; 20 EPICALCITRIOL; 2ALPHA METHYL 19 NORCALCITRIOL; ANDROSTANE DERIVATIVE; CALCIPOTRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CD 4528; CELL NUCLEUS RECEPTOR; CLOTRIMAZOLE; GEMINI; LEXACALCITOL; LG 190178; LIGAND; NEW DRUG; RALOXIFENE; SEOCALCITOL; TAMOXIFEN; TEI 9647; TX 522; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR AGONIST; VITAMIN D RECEPTOR ANTAGONIST; ZK 168281;

BIOCHEMISTRY; BONE DISEASE; CANCER; CRYSTAL STRUCTURE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; HUMAN; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; OSTEOPOROSIS; PROTEIN DOMAIN; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SIMULATION; STRUCTURE ACTIVITY RELATION;

LIGANDS; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION;

EID: 33746331105     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606777864908     Document Type: Review

References (79)

1. McKenna, N. J.; O'Malley, B. W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002, 108, 465-474.
2. Chawla, A.; Repa, J. J.; Evans, R. M.; Mangelsdorf, D. J. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294, 1866-1870.
3. Willson, T. M.; Moore, J. T. Minireview: genomics versus orphan nuclear receptors-a half-time report. Mol Endocrinol 2002, 16, 1135-1144.
4. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schfitz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M. The nuclear receptor superfamily: the second decade. Cell 1995, 83, 835-839.
5. Li, Y.; Lambert, M. H.; Xu, H. E. Activation of nuclear receptors: a perspective from structural genomics. Structure 2003, 11, 741-746.
6. Nagy, L.; Schwabe, J. W. Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 2004, 29, 317-324.
7. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engström, O.; Öhman, L.; Greene, G. L.; Gustafsson, J.- A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
8. Nolte, R. T.; Wisley, G. B.; Westin, S.; Cobb, J. E.; Lambert, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfield, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand-binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998, 395, 137-143.
9. Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; Williams, S. P.; Willson, T. M.; Kliewer, S. A.; Redinbo, M. R. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001, 292, 2329-2333.
10. Bourguet, W.; Ruff, M.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the ligand binding domain of the human nuclear receptor RXR-α. Nature 1995, 375, 377-382.
11. Renaud, J.-P.; Rochel, N.; Ruff, M.; Vivat, V.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378, 681-689.
12. Leo, C.; Chen, J. D. The SRC family of nuclear receptor coactivators. Gene 2000, 245, 1-11.
13. 3 receptor-corepressor partnership. FASEB J 2000, 14, 1455-1463.
14. Heery, D. M.; Kalkhoven, E.; Hoare, S.; Parker, M. G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 387, 733-736.
15. Hu, X.; Lazar, M. A. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 1999, 402, 93-96.
16. Moras, D.; Gronemeyer, H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell. Biol. 1998, 10, 384-391.
17. Molnar, F.; Matilainen, M.; Carlberg, C. Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. J Biol Chem 2005, 280, 26543-26556.
18. Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. G.; Cobb, J. E.; McKee, D. D.; Galardi, C. M.; Plunket, K. D.; Nolte, R. T.; Parks, D. J.; Moore, J. T.; Kliewer, S. A.; Willson, T. M.; Stimmel, J. B. Structural basis for antagonist-mediated recruitment of nuclear co- repressors by PPARα. Nature 2002, 415, 813-817.
19. Leng, X.; Tsai, S.; O'Malley, B. W.; Tsai, M.-J. Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoid X receptor. J. Steroid Biochem. Molec. Biol. 1993, 46, 643-661.
20. Keidel, S.; LeMotte, P.; Apfet, C. Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping. Mol. Cell. Biol. 1994, 14, 287-298.
21. 3 analogues is not mediated by inhibition of the AP-1 pathway, but may be related to promoter selectivity. Oncogene 1995, 11, 1853-1858.
22. Johnson, B. A.; Wilson, E. M.; Li, Y.; Moller, D. E.; Smith, R. G.; Zhou, G. Ligand-induced stabilization of PPARΥ monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol 2000, 298, 187-194.
23. Kallenberger, B. C.; Love, J. D.; Chatterjee, V. K.; Schwabe, J. W. A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nat Struct Biol 2003, 10, 136-140.
24. Pissios, P.; Tzameli, L; Kushner, P.; Moore, D. D. Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Mol Cell 2000, 6, 245-253.
25. Germain, P.; Iyer, J.; Zechel, C.; Gronemeyer, H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 2002, 415, 187-192.
26. Metivier, R.; Penot, G.; Hubner, M. R.; Reid, G.; Brand, H.; Kos, M.; Gannon, F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115, 751-763.
27. Suda, T.; Ueno, Y.; Fujii, K.; Shinki, T. Vitamin D and bone. J Cell. Biochem. 2003, 88, 259-266.
28. 3 and its analogs on growth control and tumorigenesis. Front. Biosci. 2001, 6, D820-848.
29. Carlberg, C.; Bendik, I; Wyss, A.; Meier, E.; Sturzenbecker, L. J.; Grippo, J. F.; Hunziker, W. Two nuclear signalling pathways for vitamin D. Nature 1993, 361, 657-660.
30. Toell, A.; Polly, P.; Carlberg, C. All natural DR3-type vitamin D response elements show a similar functionality in vitro. Biochem. J. 2000, 352, 301-309.
31. Kwok, R. P. S.; Lundblad, J. R.; Chrivia, J. C.; Richards, J. P.; Bächinger, H. P.; Brennan, R. G.; Roberts, S. G. E.; Green, M. R.; Goodman, R. H. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994, 370, 223-226.
32. Castillo, A. I; Jimenez-Lara, A. M.; Tolon, R. M.; Aranda, A. Synergistic activation of the prolactin promoter by vitamin D receptor and GHF-1: role of coactivators, CREB-binding protein and steroid hormone receptor coactivator-1 (SRC-1). Mol. Endocrinol. 1999, 13, 1141-1154.
33. 3 receptor in a ligand-dependent manner and enhances transactivation in a cell-free system. Genes Dev. 1998, 12, 1787-1800.
34. Rachez, C.; Lemon, B. D.; Suldan, Z.; Bromleigh, V.; Gamble, M.; Nää, A. M.; Erdjument-Bromage, H.; Tempst, P.; Freedman, L. P. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999, 398, 824-828.
35. Rochel, N.; Wurtz, J. M.; Mitschter, A.; Klaholz, B.; Moras, D. Crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell 2000, 5, 173-179.
36. Bouillon, R.; Okamura, W. H.; Norman, A. W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 1995, 16, 200-257.
37. Carlberg, C.; Mourino, A. New vitamin D receptor ligands. Expert. Opin. Ther. Patents 2003, 13, 761-772.
38. 3 analogues with two side chains. J Cell. Biochem. 2001, 81, 179-190.
39. Macias Gonzalez, M.; Samenfeld, P.; Peräkylä, M.; Carlberg, C. Compressor excess shifts the two-side chain vitamin D analog Gemini from an agonist to an inverse agonist of the vitamin D receptor. Mol Endocrinol 2003, 17, 2028-2038.
40. 3 and Gemini: purification, crystallization and preliminary X-ray diffraction analysis. J Steroid Biochem Mol Biol 2004, 89-90, 55-59.
41. 3 analogues. Steroids 2001, 66, 213-221.
42. 3 signaling. Mol. Pharmacol. 2000, 57, 375-384.
43. Quack, M.; Carlberg, C. Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs. Mol. Pharmacol. 1999, 55, 1077-1087.
44. Carlberg, C. Molecular basis of the selective activity of vitamin D analogues. J. Cell. Biochem. 2003, 88, 274-281.
45. Quack, M.; Carlberg, C. Ligand-triggered stabilization of vitamin D receptor/retinoid X receptor heterodimer conformations on DR4-type response elements. J. Mol. Biol. 2000, 296, 743-756.
46. 3 receptor. Mol. Pharmacol. 2000, 58, 1067-1074.
47. 3 receptor agonists designed for topical treatment of skin diseases. J. Invest. Dermatol. 2001, 116, 785-792.
48. 3 receptor permits sensitive interaction with agonists. Mol. Pharmacol. 2000, 57, 1206-1217.
49. Dilworth, F. J.; Williams, G. R.; Kissmeyer, A. M.; Nielsen, J. L.; Binderup, E.; Calverley, M. J.; Makin, H. L.; Jones, G. The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain signicant biological activity. Endocrinology 1997, 138, 5485-5496.
50. Tocchini-Valentini, G.; Rochel, N.; Wurtz, J. M.; Mitschler, A.; Moras, D. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad Sci. USA 2001, 98, 5491-5496.
51. 3 correlates well with gene activation. J Cell Biochem 1996, 62, 325-333.
52. Tocchini-Valentini, G.; Rochel, N.; Wurtz, J. M.; Moras, D. Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification. J. Med. Chem. 2004, 47, 1956-1961.
53. Eelen, G.; Verlinden, L.; Rochel, N.; Claessens, F.; De Clercq, P.; Vandewalle, M.; Tocchini-Valentini, G.; Moras, D.; Bouillon, R.; Verstuyf, A. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol. Pharmacol 2005, 67, 1566-1573.
54. 3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry 2004, 43, 4101-4110.
55. 3 responsive elements. J Bone Miner Res 2001, 16, 625-638.
56. Verstuyf, A.; Verlinden, L.; van Baclen, H.; Sabbe, K.; d'Hallewyn, C.; de Clercq, P.; Vanderwalle, M.; Bouillon, R. The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C- and D-rings. J. Bone Mineral. Res. 1998, 13, 549-558.
57. 3 with two side chains: interaction with its nuclear receptor and cellular actions. J Med. Chem. 2000, 43, 2719-2730.
58. Yin, D.; He, Y.; Perera, M. A.; Hong, S. S.; Marhefka, C.; Stourman, N.; Kirkovsky, L.; Miller, D. D.; Dalton, J. T. Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol. Pharmacol. 2003, 63, 211-223.
59. Fink, B. E.; Mortensen, D. S.; Stauffer, S. R.; Aron, Z. D.; Katzenellenbogen, J. A. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem. Biol. 1999, 6, 205-219.
60. 3 mimics. World Patent 2000, No. 00/10958.
61. 3. Chem. Biol. 1999, 6, 265-275.
62. Swann, S. L.; Bergh, J.; Farach-Carson, M. C.; Ocasio, C. A.; Koh, J. T. Structure-based design of selective agonists for a rickets-associated mutant of the vitamin D receptor. J Am Chem Soc 2002, 124, 13795-13805.
63. 3 analogues which selectively restore activity to a vitamin D receptor mutant associated with rickets. Org Lett 2002, 4, 3863-3866.
64. Perakyla, M.; Malinen, M.; Herzig, K. H.; Carlberg, C. Gene regulatory potential of nonsteroidal vitamin D receptor ligands. Mol Endocrinol 2005, 19, 2060-2073.
65. 3 receptor antagonists. Mol. Pharmacol. 2001, 59, 1478-1485.
66. 3 is mediated by a lack of ligand-induced vitamin D receptor interaction with coactivators. J. Biol. Chem. 2000, 275, 16506-16512.
67. 3. J. Biol. Chem. 1999, 274, 16392-16399.
68. 3-26,23-lactone analogues antagonize differentiation of human leukemia cells (HL-60 cells) but not of human acute promyelocytic leukemia cells (NB4 cells). FEBS Lett. 1999, 460, 297-302.
69. 3 analogue toward vitamin D receptor function. J. Biol. Chem. 1999, 274, 32376-32381.
70. 3 receptor for the partial agonism of carboxylic ester antagonists. J. Mol. Biol. 2002, 315, 229-238.
71. 3-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change. Mol. Endocrinol. 2000, 14, 1788-1796.
72. 3 show cell-specific actions. Chem. Biol 2000, 7, 885-894.
73. Peräkylä, M.; Molnar, F.; Carlberg, C. A structural basis for the species-specific antagonism of 26,23-lactones on vitamin D signaling. Chem Biol 2004, 11, 1147-1156.
74. 3 26,23-lactones. Org Lett 2003, 5, 4859-4862.
75. Fujishima, T.; Kojima, Y.; Azumaya, I.; Kittaka, A.; Takayama, H. Design and synthesis of potent vitamin D receptor antagonists with A-ring modifications: remarkable effects of 2α-methyl introduction on antagonistic activity. Bioorg Med Chem 2003, 11, 3621-3631.
76. Frank, C.; Molnar, F.; Matilainen, M.; Lempiänen, H.; Carlberg, C. Agonist-dependent and agonist-independent transactivations of the human constitutive androstane receptor are modulated by specific amino acid pairs. J Biol Chem 2004, 279, 33558-33566.
77. Lempiäinen, H.; Molnar, F.; Macias Gonzalez, M.; Peräkylä, M.; Carlberg, C. Antagonist- and inverse agonist-driven interactions of the vitamin D receptor and the constitutive androstane receptor with corepressor protein. Mol Endocrinol 2005, 19, 2258-2272.
78. 3 receptor by interaction with co-repressors and co-activators. J. Mol. Biol. 2000, 304, 793-801.
79. Väisänen, S.; Peräkylä, M.; Kärkkäinen, J. L.; Uskokovic, M. R.; Carlberg, C. Structural evaluation of a vitamin D analogue with two side chains. Mol Pharmacol. 2003, 63, 1230-1237.